Jounce Therapeutics, Inc. (JNCE) Financial Analysis & Valuation | Quarter Chart
Jounce Therapeutics, Inc. (JNCE)
JNCEPrice: $1.88
Fair Value: 🔒
🔒score
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on... more
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatm... more
Description
Shares
| Market Cap | $98.95M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Kimberlee Cobleigh Drapkin CPA |
| IPO Date | 2017-01-26 | CAGR | — |
| Employees | 141 | Website | jouncetx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
JNCE chart loading...
Fundamentals
Technicals
| Enterprise Value | $-83.19M | P/E Ratio | -1.96 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 1.21 | P/B Ratio | 0.53 |
| P/CF Ratio | -3.36 | P/FCF Ratio | -3.32 |
| EPS | $-0.96 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 204.75% | Gross Margin | 1% |
| Operating Margin | -0.64% | Profit Margin | -0.62% |
| ROE | -0.25% | ROA | -0.24% |
| ROCE | -0.28% | Current Ratio | 8.37 |
| Quick Ratio | 8.37 | Cash Ratio | 6.39 |
| Debt/Equity | 0.05 | Interest Coverage | — |
| Altman Z Score | 0.64 | Piotroski Score | 3 |